Skip to main content
S. 476 118th Congress Senate

Maintaining Investments in New Innovation Act

Official title: A bill to amend title XI of the Social Security Act to protect access to genetically targeted technologies.

Introduced: November 14, 2023 See on congress.gov
Health GeneticsMedicarePrescription drugs
Sign in to write a letter Sign in to watch
This bill died when the 118th Congress ended
It never became law before the 118th Congress (2023–2024) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Feb 16, 2023
Read twice and referred to the Committee on Finance.
Feb 16, 2023
Introduced in Senate
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action February 16, 2023

Read twice and referred to the Committee on Finance.

 Plain-English summary Congressional Research Service

Maintaining Investments in New Innovation Act

This bill requires drug products with genetically targeted technology to have had market approval for at least 11 years in order to qualify for the Medicare Drug Price Negotiation Program. (The program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation.)

 Related & companion bills 1
  • HR 5547 Identical bill Maintaining Investments in New Innovation Act
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Lobbying activity 4

Registered lobbyists who named this bill in their disclosure filings. Source: federal Lobbying Disclosure Act filings.

  • LMH STRATEGIC SOLUTIONS
    for IONIS PHARMACEUTICALS, INC. · California · 1st Quarter 2025 (Jan 1 - Mar 31)
  • TIBER CREEK HEALTH STRATEGIES, INC.
    for NOVARTIS · District of Columbia · 1st Quarter 2025 (Jan 1 - Mar 31)
  • FORBES-TATE
    for NOVARTIS, INC. · District of Columbia · 1st Quarter 2025 (Jan 1 - Mar 31)
  • FORBES-TATE
    for IONIS PHARMACEUTICAL, INC. · California · 1st Quarter 2025 (Jan 1 - Mar 31)

Bodies those filers lobbied

A filing lists the bills it worked on and the parts of government it contacted in separate sections, so these are the bodies those filers named anywhere in the filing, not a per-bill breakdown.

 Cosponsors 3
All 3 Republican 3
R
Daines, Steve
Montana · Jun 17, 2024
 R
Budd, Ted
North Carolina · Nov 14, 2023
 R
Blackburn, Marsha
Tennessee · Feb 16, 2023
Cite this page click to expand
APA
U.S. Congress. (2026). S. 476: Maintaining Investments in New Innovation Act. 118th Congress. Open America. https://openamerica.io/bill/118-S-476/
MLA
"S. 476: Maintaining Investments in New Innovation Act." 118th Congress, 2026, Open America, https://openamerica.io/bill/118-S-476/.
Bluebook (legal)
S. 476, 118th Cong. (2026), https://openamerica.io/bill/118-S-476/.
Markdown link
[S. 476: Maintaining Investments in New Innovation Act](https://openamerica.io/bill/118-S-476/)
Report a problem